- Home
- ASTL vs CLLS Comparison
ASTL vs CLLS Comparison
Compare ASTL & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASTL | CLLS |
|---|---|---|
| Founded | 1902 | 1999 |
| Country | Canada | France |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 467.0M | 374.2M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | ASTL | CLLS |
|---|---|---|
| Price | $4.70 | $3.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 1.5M | 35.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.17% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $32.58 |
| Revenue Next Year | N/A | $20.68 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.02 | $1.10 |
| 52 Week High | $7.25 | $5.48 |
Technical Indicators
Market Signals| Indicator | ASTL | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 51.84 | 45.66 |
| Support Level | $4.20 | $3.41 |
| Resistance Level | $5.25 | $4.46 |
| Average True Range (ATR) | 0.35 | 0.17 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 47.19 | 40.00 |
Price Performance
Historical ComparisonAbout ASTL Algoma Steel Group Inc.
Algoma Steel Group Inc is a fully integrated steel producer of hot and cold rolled steel products, including coiled sheet and plate, strategically located. The firm operates in a single segment of basic steel production including sheets, plates, slabs, and freights. The company's revenue is generated from contracts to produce, ship, and deliver steel products Geographically it serves Canada, the United States, and the rest of the world, whilst driving key revenue from domestic sales. The company generates the majority of its revenue from the sale of Steel sheets and strips.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.